Clinical trials: Recurrent Gastric Cancer
Bladder Cancer, Breast Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
RATIONALE: The LMB-9 immunotoxin may be able to locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced solid tumors.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00019435
- Testing
- LMB-9 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Ependymoma
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Approximately 90% of children with malignant brain tumors that have recurred or relapsed after receiving conventional therapy will die of disease.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma
- Trial name
- NCT03434262
- Testing
- Gemcitabine, ribociclib, sonidegib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- St. Jude Children's Research Hospital
Gastric Cancer Patient
The Relationship Between Time Perspective, Fear of Cancer Recurrence, Rumination, and Catastrophizing in Gastric Cancer Survivors
The temporal perspective provides a theory oriented to temporal insights that can shed light on the role of cognitive coping styles in the formation of fear of cancer recurrence.
- Trial name
- NCT06606080
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Ting Wang
Anal Cancer, Colorectal Cancer
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00003427
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Gastric Cancer
Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different combinations and combining them with interferon alfa and G-CSF may kill more tumor…
- Trial name
- NCT00003172
- Testing
- filgrastim, recombinant interferon alfa, docetaxel
- Where
- 25 sites in United States, South Africa
- Sponsor
- Eastern Cooperative Oncology Group
Gastric Cancer
Feasibility Study of Intraperitoneal Paclitaxel
This is a single arm phase 2 trial evaluating the efficacy and tolerability of intraperitoneal paclitaxel with oxaliplatin and capecitabine in advanced gastric cancer patients with peritoneal metastasis and/or cancer cells on…
- Trial name
- NCT01739894
- Testing
- IP Paclitaxel
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- National University Hospital, Singapore
Gastric and Esophagogastric Junction Adenocarcinoma
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction adenocarcinoma…
- Trial name
- VESTIGE (NCT03443856)
- Testing
- Nivolumab and Ipilimumab, chemotherapy
- Where
- 28 sites in Czechia, France and 7 more
- Volunteers
- 197 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Stomach Neoplasms
A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer
The purpose of this study is to assess the effectiveness, safety, and actual treatment status of first-line nivolumab plus chemotherapy in participants with untreated advanced / recurrent gastric cancer in a Japanese real-world…
- Trial name
- G-KNIGHT (NCT05334719)
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Bristol-Myers Squibb
Gastric Cancer
Systemic Oxidative Stress Score as a Predictor of Gastric Cancer Survival and Recurrence Risk
The Systemic Oxidative Stress Score (SOSS) , a comprehensive score reflecting the oxidative stress conditions in the microenvironment, can independently and effectively predict tumor burden and long-term prognosis in GC patients.
- Trial name
- NCT06337279
- Where
- China
- Volunteers
- 3,820 people
- Sponsor
- Fujian Medical University
Gastro-Intestinal Stromal Tumour
Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence
The objective is to compare the efficacy and safety of masitinib at 4.5 mg/kg/day to placebo in the treatment of patients with localized, primary gastrointestinal stromal tumor (GIST) after complete surgery and with high risk of…
- Trial name
- NCT02009423
- Testing
- Masitinib
- Volunteers
- 7 people
- Sponsor
- AB Science
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.
- Trial name
- NCT02625623
- Testing
- Avelumab, Irinotecan, Paclitaxel
- Where
- 75 sites in United States, Australia and 8 more
- Volunteers
- 371 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Solid Tumor, Lymphoma
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
This is a single arm Phase 2 study of the combination of adenoviral p53 (Ad-p53) gene therapy administered intra-tumorally with approved immune checkpoint inhibitors in patients with recurrent or metastatic cancers.
- Trial name
- NCT03544723
- Testing
- Ad-p53
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- MultiVir, Inc.
Esophageal Cancer, Gastroesophageal Cancer
Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
Surgery with or without neoadjuvant therapy is usually used as the treatment for resectable esophageal cancer or esophageal- gastric junction cancer.
- Conditions
- Esophageal Cancer, Gastroesophageal Cancer, Immunotherapy, Adjuvant
- Trial name
- NCT04688801
- Testing
- Chemotherapy Drugs, Cancer, Immunotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The Second Hospital of Shandong University
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT01498289
- Testing
- FOLFOX regimen, docetaxel, fluorouracil
- Where
- 508 sites in United States
- Volunteers
- 213 people
- Sponsor
- SWOG Cancer Research Network
Gastric Cancer
Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC.
A phase I/II study is conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of a combination chemotherapy using CPT-11 and Paclitaxel in pre-treated patients with metastatic gastric…
- Trial name
- NCT00209612
- Testing
- Taxol, Campt, Topotesin
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
Gastric Cancer (Diagnosis)
A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy
To explore the efficacy and safety of sintilimab combined with ramucirumab and paclitaxel in the treatment of advanced gastric cancer patients with short-term recurrence after postoperative adjuvant therapy, and to identify…
- Trial name
- NCT07669740
- Testing
- Sintilimab Combined with Ramucirumab and Paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Solid Tumor, Soft Tissue Sarcoma
A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors
This clinical study is to investigate the safety and tolerability of CAR modified autologous T cells (CCT301-59) in subjects with recurrent or refractory solid tumors.
- Conditions
- Solid Tumor, Soft Tissue Sarcoma, Gastric Cancer, Pancreatic Cancer
- Trial name
- CAR (NCT03960060)
- Testing
- CCT301-59
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai PerHum Therapeutics Co., Ltd.
Colorectal Cancer, Esophageal Cancer
Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of two different vaccines in treating patients who have cancer of the…
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00012246
- Testing
- carcinoembryonic antigen peptide 1-6D, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Ovarian Clear Cell Carcinoma, Endometrial Cancer
TR115 in ARID1A-Mutated Advanced Solid Tumors
This is an open-label, multicenter, exploratory Phase II study to evaluate the efficacy and safety of TR115, an EZH2 inhibitor, in patients with advanced solid tumors carrying ARID1A gene mutations.
- Conditions
- Ovarian Clear Cell Carcinoma, Endometrial Cancer, Stomach Cancer Recurrent, Urinary Bladder Cancer
- Trial name
- NCT07793318
- Testing
- TR115
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tarapeutics Science Inc.